文献速递淋巴瘤

microRNA-29b水平降低与皮肤T细胞淋巴瘤中BRD4介导的癌基因激活相关

Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.
PubMed 文献 · Blood · 2017-11-27

本研究探讨皮肤T细胞淋巴瘤(CTCL)中microRNA-29b(miR-29b)下调与表观遗传阅读器BRD4过表达的关系。患者CD4+ T细胞中miR-29b水平低于健康供者,且与BRD4呈负相关;BRD4在全基因组启动子和增强子区域占据增加,促进NOTCH1、RBPJ及IL-15受体复合物表达,增强IL-15自分泌信号。在IL-15转基因小鼠CTCL模型中,硼替佐米恢复miR-29b或JQ1抑制BRD4均可阻止疾病进展。作者认为靶向该通路可能对CTCL患者有效。

要点

  • CTCL患者CD4+ T细胞中miR-29b水平低于健康供者细胞,且与BRD4表达呈负相关。
  • 患者CD4+ T细胞中BRD4在启动子和增强子区域的全基因组占据增加,驱动NOTCH1、RBPJ及IL-15受体复合物表达。
  • 在IL-15转基因小鼠CTCL模型中,硼替佐米恢复miR-29b或JQ1抑制BRD4均可阻止CTCL进展。

核心结论

  • 本研究描述了一条涉及IL-15、miR-29b和BRD4的新型致癌通路,并认为靶向这些组分可能是对CTCL患者潜在有效的治疗。

研究设计与样本

  • 研究使用患者CD4+ T细胞与健康供者细胞比较miR-29b水平,并采用miR-29b-/-小鼠细胞验证miR-29b与BRD4的负相关关系。
  • 通过染色质免疫沉淀测序分析CTCL患者CD4+ T细胞中BRD4的全基因组占据。
  • 在IL-15转基因小鼠CTCL模型中,分别通过硼替佐米恢复miR-29b水平或JQ1直接抑制BRD4结合来干预BRD4介导的发病过程。

主要发现

  • 患者CD4+ T细胞中miR-29b水平低于健康供者细胞,且患者细胞与miR-29b-/-小鼠细胞均显示miR-29b与BRD4呈负相关,BRD4在这些细胞中过表达。
  • 染色质免疫沉淀测序显示CTCL患者CD4+ T细胞中BRD4在启动子和增强子区域的全基因组占据增加。
  • BRD4结合的累积效应导致肿瘤相关基因NOTCH1和RBPJ以及IL-15受体复合物表达增加,后者增强IL-15自分泌信号。
  • 在IL-15转基因小鼠CTCL模型中,硼替佐米恢复miR-29b水平或JQ1抑制BRD4结合均阻止CTCL进展。

临床怎么用

  • 作者认为靶向IL-15、miR-29b和BRD4这些组分可能是对CTCL患者潜在有效的治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

MicroRNA (miRNA) dysregulation is a hallmark of cutaneous T-cell lymphoma (CTCL), an often-fatal malignancy of skin-homing CD4+ T cells for which there are few effective therapies. The role of microRNAs (miRs) in controlling epigenetic modifier-dependent transcriptional regulation in CTCL is unknown. In this study, we characterize a novel miR dysregulation that contributes to overexpression of the epigenetic reader bromodomain-containing protein 4 (BRD4). We used patient CD4+ T cells to show diminished levels of miR-29b compared with healthy donor cells. Patient cells and miR-29b-/- mouse cells revealed an inverse relationship between miR-29b and BRD4, the latter of which is overexpressed in these cells. Chromatin immunoprecipitation and sequencing analysis revealed increased genome-wide BRD4 occupancy at promoter and enhancer regions in CD4+ T cells from CTCL patients. The cumulative result of BRD4 binding was increased expression of tumor-associated genes such as NOTCH1 and RBPJ, as well as the interleukin-15 (IL-15) receptor complex, the latter enhancing IL-15 autocrine signaling. Furthermore, we confirm the in vivo relevance of this pathway in our IL-15 transgenic mouse model of CTCL by showing that interference with BRD4-mediated pathogenesis, either by restoring miR-29b levels via bortezomib treatment or by directly inhibiting BRD4 binding via JQ1 treatment, prevents progression of CTCL. We describe a novel oncogenic pathway featuring IL-15, miR-29b, and BRD4 in CTCL and suggest targeting of these components as a potentially effective therapy for CTCL patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kohnken R, Wen J, Mundy-Bosse B, et al. Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. Blood. 2017. PMID: 29180399. doi:10.1182/blood-2017-09-805663

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。